Filing Details

Accession Number:
0001178913-12-002171
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-08-07 11:47:24
Reporting Period:
2012-07-31
Filing Date:
2012-08-07
Accepted Time:
2012-08-07 11:47:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1451980 Biocancell Therapeutics Inc. BICL Pharmaceutical Preparations (2834) 204630076
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1468950 Ltd. Industries Biotechnology Clal Hogi Tower, 12A Abba Hillel Silver St.
Ramat Gan L3 52506
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-31 4,147,171 $0.22 16,591,408 No 4 C Direct
Common Stock Acquisiton 2012-07-31 10,731,726 $0.22 27,323,134 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Debenture Disposition 2012-07-31 0 $0.00 0 $0.22
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2008-07-30 2012-07-31 No 4 C Direct
Footnotes
  1. The 4,147,171 shares of Common Stock reported acquired herein are issuable to Clal Biotechnology Industries Ltd. ("CBI") as a result of the conversion of convertible debentures in a principal face amount of $800,000 (the "Debentures") at a conversion price per share of New Israeli Shekel ("NIS") 0.87. Such conversion price is due to adjustments of the initial conversion price of the Debentures, which was initially $0.716, in accordance with the terms of the Debenture. The conversion prices indicated in the table are based on the exchange rate of NIS and US dollar reported by the Bank of Israel on August 3, 2012 (NIS 4.007 for US$1.00).
  2. The 10,731,726 shares of Common Stock reported acquired herein were acquired through a private placement that was executed in NIS at a price of NIS 0.87 per share. The price indicated in the table is based on the exchange rate of NIS and US dollar reported by the Bank of Israel on August 3, 2012 (NIS 4.007 for US$1.00).